Abstract 485P
Background
Gliomas are primary tumors originating in the brain parenchyma known for their aggressive and diffusive behavior. The diagnosis is based on pathological anatomy that consists of morphological, immunohistochemical and molecular analysis. Simulating the behavior of gliomas in mathematical modeling is a powerful tool in evaluating tumor growth, as well as assisting in therapeutic decision-making.
Methods
We propose a mathematical model of continuous evolution of glioma that seeks to predict its spatio-temporal evolution through interactions of cell populations (concentration (C) of cancer cells “C_C” and dead cells “C_m”) with microenvironment (Mev) nutrients (nutrient C “ C_n”). As it is a complex phenomenon, this model takes into account the process of cell division (proliferation), death and motility. The cell division rate is assumed to follow a logistic model where the proliferation coefficient “r(C_C, C_n)” will be evaluated depending on the C of diseased cells (C_C) and nutrients (oxygen - C_n). The motility coefficient (D_c) and the Mev support capacity (C_Tmax) vary spatially as presented in the literature. For the cell death rate, it was considered that this is a function of the nutrient concentration “k_cm (C_n)” in the Mev. The non-linear system of partial differential equations, for the variables Cc (t,x), Cm (t,x), and Cn (t,x),was solved by the Method of Lines (MOL).
Results
In table we present some results for the average tumor cell population (Nc - Cells) as a function of time (in the limit cases when kn and kcm are very small and a = 0, 62.5) and comparisons with literature data. Nc - Cells for a = 0 and a = 62.5. Table: 485P
t (days) | a = 0 | a = 62.5 | ||||
Present | Ref. [1] | Ref. [2] | Present | Ref. [1] | Ref. [2] | |
1080 | 1710 | — | 1752 | 3116 | 3134 | 3126 |
Conclusions
Results for C, Nc - Cells, average tumor size and growth rate were obtained and compared to those available in the literature, showing that the presente model, with contributions that make it more rigorous and complex, appears to be physically coherent and capable of evaluating the spatio-temporal tumor growth.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
469P - Detection of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) in patients with glioblastoma treated in phase I clinical trial
Presenter: Marie Porte
Session: Poster session 16
470P - Mitochondrial ribosomal proteins (MRPs) in glioblastoma multiforme: Omics approach
Presenter: Jehad Yasin
Session: Poster session 16
471P - PTEN alteration as a predictor of second-line efficacy in patients with recurrent IDHwt-glioblastoma
Presenter: Eugenia Cella
Session: Poster session 16
472P - Comprehensive quinomics assessment of BPM31510IV treatment in advanced glioblastoma multiforme patients
Presenter: Seema Nagpal
Session: Poster session 16
473P - A novel machine learning (ML) model integrating clinical and molecular data to predict response to second-line treatment in recurrent IDHwt-glioblastoma (rGBM)
Presenter: Maurizio Polano
Session: Poster session 16
474P - Potassium inward rectifier channel subfamily J member 11 mRNA expression in glioma and its significance in predicting prognosis and chemotherapy sensitivity
Presenter: kaijia zhou
Session: Poster session 16
Resources:
Abstract
475P - Optimising genomic testing for patients with central nervous system (CNS) tumours using oxford nanopore technology
Presenter: Alona Sosinsky
Session: Poster session 16
476P - The role of androgen receptor expression and epigenetic regulation in adult-type diffuse gliomas
Presenter: VINCENZO DI NUNNO
Session: Poster session 16
477P - ENHO's protective role in lower grade glioma
Presenter: Osama Younis
Session: Poster session 16